ArQule says Kyowa's ATTENTION deficit won't affect MARQUEE Phase III tivantinib study
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has stopped patient enrollment in the Phase III ATTENTION clinical trial in Asia for the ArQule cancer drug tivantinib due to cases of interstitial lung disease (ILD), but ArQule says the news will not impact its ongoing 1,000-patient Phase III MARQUEE trial conducted with Daiichi Sankyo in the Americas, Europe and other regions.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.